top of page

Navigating the Path to Regulatory Approval: Preparing an eCTD Submission for a New Drug in the US


The process of bringing a new drug to market involves numerous steps, with one critical milestone being the submission of a regulatory dossier to health authorities. In the United States, the electronic Common Technical Document (eCTD) format has become the standard for regulatory submissions, streamlining the review process and enhancing communication between sponsors and regulatory agencies. In this blog, we'll highlight key steps involved in preparing an eCTD submission for a new drug in the US.

Understanding the eCTD Format:

The eCTD format organizes regulatory documents into a standardized electronic format, facilitating the review and assessment process by regulatory agencies such as the Food and Drug Administration (FDA). It consists of five main modules: administrative information, quality, nonclinical study reports, clinical study reports, and overall summaries. Each module contains specific documents relevant to the drug development process, including chemistry, manufacturing, and controls (CMC) data, preclinical and clinical study reports, labeling information, and regulatory correspondence.

Compilation of Documentation:

The first step in preparing an eCTD submission is compiling all relevant documentation required by regulatory authorities. This includes comprehensive information on the drug's chemistry, manufacturing process, and controls, as well as preclinical and clinical study data demonstrating safety and efficacy. Additionally, sponsors must include labeling information, risk management plans, and any additional documents requested by regulatory agencies.

Document Formatting and Organization:

Once the required documentation has been compiled, it must be formatted and organized according to eCTD specifications. This involves converting documents into electronic format and assigning them to the appropriate sections within the eCTD structure. Each document should be properly indexed, bookmarked, and hyperlinked to facilitate navigation and review by regulatory reviewers.

Validation and Quality Assurance:

Before submission, it's crucial to perform a thorough validation and quality assurance review to ensure the accuracy, completeness, and integrity of the eCTD dossier. This includes verifying that all documents meet regulatory requirements, adhere to formatting guidelines, and are free from errors or discrepancies. Sponsors should also conduct a technical validation using validation software to identify any potential issues or deficiencies in the submission package.

Submission to Regulatory Authorities:

Once the eCTD dossier has been validated and finalized, it can be submitted to regulatory authorities through the FDA's Electronic Submissions Gateway (ESG). Sponsors must adhere to the FDA's published guidance and timelines for submission, ensuring that all required forms and documents are included. After submission, sponsors can track the progress of their application through the FDA's Electronic Submission Tracking System (ESTS) and respond promptly to any requests or queries from regulatory reviewers.


Preparing an eCTD submission for a new drug in the US is a complex and multifaceted process that requires careful planning, attention to detail, and adherence to regulatory requirements. By understanding the eCTD format, compiling comprehensive documentation, formatting and organizing documents appropriately, conducting thorough validation and quality assurance, and submitting the dossier to regulatory authorities in a timely manner, sponsors can navigate the path to regulatory approval with confidence and efficiency. Contact us to learn more how Trinity M Consulting can help with your next eCTD submission.



bottom of page